The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is used to counsel patients regarding the risk of transplantation and selection of conditioning regimens. Pulmonary disease, most frequently demonstrated by a decreased diffusion capacity of carbon monoxide (DLCO), is the most prevalent comorbidity captured by the HCT-CI. The HCT-CI was validated using the Dinakara method for adjusting DLCO for Hb, but our institution and others utilize the Cotes method. The purpose of this study was to determine the impact of using the Cotes method rather than the Dinakara method on the HCT-CI score. We reviewed pretransplant pulmonary function tests in 73 patients who underwent allogeneic hematopoietic SCT. Patients were stratified into low, intermediate or high-risk groups based on HCT-CI scores of 0, 1-2 or X3, respectively. We found that compared with the Dinakara method, the Cotes method increased the HCT-CI score in 45% of patients and resulted in total HCT-CI scores predictive of higher non-relapse mortality in 33% of patients. These results indicate that if an institution uses the Cotes method to adjust DLCO for Hb, their patients may be counseled to expect a higher risk of mortality than is actually predicted by the HCT-CI, and may be excluded from transplantation. Therefore, unless the HCT-CI is validated using other methods for correcting DLCO for Hb, the Dinakara method should be used.
INTRODUCTION
Allogeneic hematopoietic SCT (HCT) offers potentially curative therapy for patients with hematologic malignancies, but also carries significant risks. Assessing potential risk versus benefit is a significant challenge for transplant physicians. Scoring systems to predict transplant-related mortality provide critical data to assist in counseling patients regarding risk of transplantation and selecting appropriate conditioning regimens.
The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) has recently emerged as an important tool for pre-transplant risk assessment. 1 Originally developed at the Fred Hutchinson Cancer Research Center (FHCRC) as a modification of the Charlson Comorbidity Index (CCI), 2 the HCT-CI has now been assessed in numerous transplant settings. In multiple studies, the index has demonstrated effective risk stratification for patients treated for AML, myelodysplastic syndrome, non-Hodgkin's and Hodgkin's lymphoma, CLL and multiple myeloma. [3] [4] [5] [6] [7] [8] [9] [10] [11] In published reports, non-relapse mortality is predicted by stratifying patients into either low, intermediate and high-risk groups based on HCT-CI scores of 0, 1-2 or X3, 1, 7 or low-and high-risk groups based on HCT-CI scores of 0-2 or X3.
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When paired with additional factors, including Karnofsky performance score and disease-specific markers, the index provides increased predictive power. 12, 13 Several smaller studies have questioned the validity of the HCT-CI. [14] [15] [16] [17] [18] Sample size, lack of complete data sets and use of more historic patient data have been suggested as possible explanations for discrepancies.
Pulmonary disease is the most prevalent comorbidity captured by the HCT-CI. 1 It is defined by abnormalities in forced expiratory volume in 1 s (FEV1) or diffusion capacity of carbon monoxide (DLCO). At the University of Colorado Denver, we observed the prevalence of severe pulmonary disease, most often defined by a reduced DLCO rather than FEV1, to be significantly higher than that reported in the FHCRC data set. 1 This led us to examine our method for calculating DLCO, which may vary from institution to institution. We found that the equation for adjusting DLCO for Hb used in the development of the HCT-CI differs from the equation used in our institution. 19 Whereas our calculation is based on the equation by Cotes et al., 20 the equation used at the FHCRC is based on Dinakara et al. 19, 21 As the American Thoracic Society (ATS) and the European Respiratory Society (ERS) guidelines recommend that the Cotes equation be applied when adjusting DLCO for Hb, 22 other institutions are also using this equation.
The objectives of this study were to compare the adjusted DLCO for Hb using the Cotes and Dinakara equations in a population of patients prior to HCT, and to determine the impact that the adjusted DLCO has on the HCT-CI score and risk-group stratification. FEV1 was performed using standard technique and was expressed as a percent of predicted according to standard reference equations. Patients were defined as having moderate pulmonary disease if their measured DLCO or FEV1 was 66-80% or if they complained of dyspnea with slight activity. Severe pulmonary disease was defined as a DLCO or FEV1 p65%, dyspnea at rest, or if the patient required oxygen chronically. HCT-CI scores were determined for all patients (Table 1) . Patients were stratified into low (0 points), intermediate (1-2 points), and high risk (X3 points) groups on the basis of their total scores. Continuous variables were compared using Student's t-test. Two-sided P-values o0.05 were considered statistically significant.
MATERIALS AND METHODS

RESULTS
Pulmonary function tests from 73 patients were included in the analysis. Pulmonary function tests were obtained a median of 20 days (range 5-84) prior to transplant. The mean age at the time of pulmonary testing was 58 years (range 20-72). Fifty-one percent of patients were male and 49% were female. Diseases, conditioning regimens, donor types and non-pulmonary comorbidities are summarized in Table 2 .
The mean Hb was 10.1 g/dL (range 7.2-16.1 g/dL). The mean %DLCO adjusted for Hb using the Cotes method was 61% compared to 77% using the Dinakara method (Po0.001). The difference in adjusted %DLCO was significantly more pronounced in patients with Hb o12.0 g/dL (Table 3) .
Overall, 50 patients (68%) met the criteria for moderate to severe pulmonary disease using the Dinakara method compared with the 64 patients (87%) using the Cotes method (Table 4) . Using the Dinakara method, the percentage of patients meeting the definition of moderate or severe pulmonary disease defined by FEV1 only, DLCO only or both FEV1 and DLCO was 8, 82 and 10%, respectively. In comparison, when the Cotes method was used, these percentages were 3, 94 and 3%, respectively. Compared with the Dinakara method, when the Cotes method was applied, the total HCT-CI score increased by 1 point in 18 patients (25%), 2 points in 11 patients (15%) and 3 points in 4 patients (5%). Only one patient's score was decreased by the Cotes method. The increase in score resulted in one patient (1%)
DISCUSSION
The HCT-CI was developed as a pre-transplant risk-assessment tool for patients undergoing HCT. Numerous studies have validated the efficacy of the HCT-CI, and many transplant physicians now use it as a tool to counsel patients regarding risks of transplant and to help select appropriate conditioning regimens. Pulmonary disease, most commonly defined by a reduction in DLCO, is the most frequent comorbidity detected by the HCT-CI. The HCT-CI was developed at the FHCRC, where the Dinakara equation for adjusting DLCO for Hb is used. However, our center and others use the Cotes method that has been recommended by ATS/ERS guidelines. 22 By comparing these two methods for adjusting DLCO, we show that using the Cotes method results in a comorbidity index score associated with an increased risk of Adjusting DLCO for Hb and the HCT-CI DG Coffey et al non-relapse mortality in a third of patients. This technical issue has profound implications, but can easily be corrected. The Dinakara and Cotes equations were derived from small groups of patients with differing characteristics, which may explain the discrepancy between the two methods. The Cotes equation was based on 20 female subjects with iron-deficiency anemia in whom DLCO was measured before and after iron replacement. 20 In contrast, the Dinakara equation was derived from 31 male and 19 female subjects, in whom 28 had anemia due to kidney disease, hemolysis, aplastic anemia, iron deficiency or folic acid deficiency. 21 These groups of patients may not be representative of those undergoing HCT, who tend to have a greater degree of anemia and undergo frequent blood transfusions. Indeed, we observed the greatest discrepancy between the two methods in those patients with the lowest Hb concentrations. Others have reported similar findings; Rodríguez-Roisin et al. 24 found that patients with aplastic anemia have a lower DLCO, using the Cotes correction, as compared to leukemic patients prior to HCT and that this difference was due to a lower Hb level. This issue was addressed by Marrades et al., 25 who derived a new equation based on patients with anemia due to chronic renal disease which was validated in patients with hematologic malignancy.
An additional factor beyond adjusting DLCO for Hb that could have an impact on the HCT-CI score is the choice of a standard reference equation used to calculate %DLCO. As the ATS/ERS guidelines do not recommend one particular reference equation, each pulmonary function laboratory is left to decide their own reference equation. In this study, we used the Crapo reference equation 23 that is also used by FHCRC. In the future, investigators should publish their reference equations along with the method used to adjust DLCO for Hb.
By comparing the Cotes and Dinakara methods for adjusting DLCO for Hb, we show that the method used may significantly affect the interpretation of the HCT-CI. We found that the Cotes method may overestimate non-relapse mortality predicted by the HCT-CI in as many as a third of patients. We recommend that for the purpose of determining a patient's HCT-CI, either the Dinakara method be used or the index be revalidated with an alternative equation for adjusting DLCO for Hb. Adjusting DLCO for Hb and the HCT-CI DG Coffey et al
